{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:22Z","timestamp":1787243362099,"version":"build-2736575974"},"reference-count":24,"publisher":"Scientific Scholar","content-domain":{"domain":["cytojournal.com"],"crossmark-restriction":true},"short-container-title":["Cytojournal"],"abstract":"\n Objectives:<\/jats:title>\n Pleural fluid evaluation is an effective modality for identifying actionable genetic mutations to guide therapy in lung carcinoma. Clinicians requesting molecular studies often send large volumes of fluid to be processed that is not possible or cost effective and is hence not standard of practice in most cytopathology laboratories. We wanted to establish the characteristics of an adequate specimen that would yield reliable results with current molecular testing platforms.<\/jats:p>\n <\/jats:sec>\n \n Material and Methods:<\/jats:title>\n A review of 500 malignant pleural effusions, from pulmonary and non-pulmonary sources, was undertaken over a 4-year period. Of these 44 cases (from 42 patients) that were positive for primary lung adenocarcinoma were included in the study. Molecular analysis was performed on 42 specimens. A complete next generation sequencing (NGS) panel was performed on 36 specimens. Individual testing for estimated glomerular filtration rate, KRAS, anaplastic lymphoma kinase, and ROS1 was performed on six specimens. The number of malignant cells and proportion of tumor to non-tumor nucleated cells (T: NT) on cell blocks was recorded as <20%, 20\u201350% and >50%.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The minimum volume on which a complete NGS panel could be performed was 20 ml with cell count of 1000 and T: NT proportion of 20\u201350%. The minimum number of tumor cells required for successful molecular analysis for T: NT proportion of <20%, 20\u201350%, and >50% was 300, 250, and 170 cells, respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n We concluded that tumor cell proportion, rather than specimen volume, is of prime importance for determining the efficacy of pleural fluid for molecular studies. Evaluation of both absolute and relative numbers of tumor cells is critical for assessing the adequacy and predicting successful yield for molecular analysis.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/cytojournal_18_2021","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T05:07:22Z","timestamp":1643951242000},"page":"7","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Adequacy of pleural fluid cytology for comprehensive molecular analysis of lung adenocarcinoma: Experience of a large health-care system"],"prefix":"10.25259","volume":"19","author":[{"given":"Siddhartha Dilip","family":"Dalvi","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, United States,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chau","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, United States,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Sajjan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, United States,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baidarbhi","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, United States,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Karam","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, United States,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Khutti","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, United States,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Gimenez","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, United States,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasturi","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, United States,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"10.25259\/Cytojournal_18_2021\/ref-1","first-page":"4743","article-title":"Pleural effusion as a significant prognostic factor in non-small cell lung cancer","volume":"17","author":"Naito","year":"1997","journal-title":"Anticancer Res"},{"key":"10.25259\/Cytojournal_18_2021\/ref-2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31807a2f81","article-title":"The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.25259\/Cytojournal_18_2021\/ref-3","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1183\/09031936.93.06101544","article-title":"Thoracoscopy: Present diagnostic and therapeutic indications","volume":"6","author":"Loddenkemper","year":"1993","journal-title":"Eur Respir J"},{"key":"10.25259\/Cytojournal_18_2021\/ref-4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0002-9610(99)80257-8","article-title":"Diagnosis and management of malignant pleural effusions","volume":"170","author":"Fenton","year":"1995","journal-title":"Am J Surg"},{"key":"10.25259\/Cytojournal_18_2021\/ref-5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/cncy.22021","article-title":"Ancillary studies in pleural, pericardial, and peritoneal effusion cytology","volume":"126","author":"Sundling","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"10.25259\/Cytojournal_18_2021\/ref-6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/ajcp\/72.1.48","article-title":"Comparison of the diagnostic values of biopsies of the pleura and cytologic evaluation of pleural fluids","volume":"72","author":"Frist","year":"1979","journal-title":"Am J Clin Pathol"},{"key":"10.25259\/Cytojournal_18_2021\/ref-7","first-page":"31","volume-title":"Cytopathologic Diagnosis of Serous Fluids","year":"2007","edition":"1st ed"},{"key":"10.25259\/Cytojournal_18_2021\/ref-8","author":"The National Comprehensive Cancer Network","year":"2015"},{"key":"10.25259\/Cytojournal_18_2021\/ref-9","doi-asserted-by":"publisher","first-page":"828","DOI":"10.5858\/arpa.2012-0720-OA","article-title":"Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology","volume":"137","author":"Lindeman","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.25259\/Cytojournal_18_2021\/ref-10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.lungcan.2005.02.016","article-title":"EGFR mutations in malignant pleural effusion of non-small cell lung cancer: A case report","volume":"49","author":"Huang","year":"2005","journal-title":"Lung Cancer"},{"key":"10.25259\/Cytojournal_18_2021\/ref-11","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1002\/ijc.22190","article-title":"Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer","volume":"119","author":"Soh","year":"2006","journal-title":"Int J Cancer"},{"key":"10.25259\/Cytojournal_18_2021\/ref-12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/JTO.0b013e31824cc46b","article-title":"Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma","volume":"7","author":"Tsai","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.25259\/Cytojournal_18_2021\/ref-13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.lungcan.2007.01.014","article-title":"EGFR volume of pleural fluid required for accurate volume of pleural fluid required for accurate predicts tumor responsiveness and resistance to gefitinib","volume":"56","author":"Soh","year":"2007","journal-title":"Lung Cancer"},{"key":"10.25259\/Cytojournal_18_2021\/ref-14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/cytojournal.cytojournal_20_19","article-title":"CellBlockistry: Chemistry and art of cell-block making-a detailed review of various historical options with recent advances","volume":"16","author":"Shidham","year":"2019","journal-title":"Cytojournal"},{"key":"10.25259\/Cytojournal_18_2021\/ref-15","first-page":"55","volume-title":"Cytopathologic Diagnosis of Serous Fluids","year":"2007","edition":"1st ed"},{"key":"10.25259\/Cytojournal_18_2021\/ref-16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.25259\/Cytojournal_3_2021","article-title":"Cell-blocks and other ancillary studies (including molecular genetic tests and proteomics)","volume":"18","author":"Shidham","year":"2021","journal-title":"Cytojournal"},{"key":"10.25259\/Cytojournal_18_2021\/ref-17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2303.2010.00786.x","article-title":"An investigation of adequate volume for the diagnosis of malignancy in pleural fluids","volume":"22","author":"Thomas","year":"2011","journal-title":"Cytopathology"},{"key":"10.25259\/Cytojournal_18_2021\/ref-18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2303.2010.00786.x","article-title":"The diagnostic yield of pleural fluid cytology in malignant pleural effusions","volume":"41","author":"Ong","year":"2000","journal-title":"Singapore Med J"},{"key":"10.25259\/Cytojournal_18_2021\/ref-19","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0119-CP","article-title":"Collection and handling of thoracic small biopsy and cytology specimens for ancillary studies: Guideline from the college of American pathologists in collaboration with the American college of chest physicians, association for molecular pathology, American society of cytopathology, American thoracic society, pulmonary pathology society, papanicolaou society of cytopathology, society of interventional radiology, and society of thoracic radiology","author":"Roy-Chowdhuri","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.25259\/Cytojournal_18_2021\/ref-20","first-page":"72","article-title":"Thoracocentesis for potential malignancy: Does volume matter?","volume":"11","author":"Buckley","year":"2008","journal-title":"Hong Kong J Radiol"},{"key":"10.25259\/Cytojournal_18_2021\/ref-21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cncy.21452","article-title":"A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: A retrospective analysis of 2540 cases","volume":"122","author":"Rooper","year":"2014","journal-title":"Cancer Cytopathol"},{"key":"10.25259\/Cytojournal_18_2021\/ref-22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/0970-2113.197120","article-title":"The minimum volume of pleural fluid required to diagnose malignant pleural effusion: A retrospective study","volume":"34","author":"Wu","year":"2017","journal-title":"Lung India"},{"key":"10.25259\/Cytojournal_18_2021\/ref-23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2013.04.023","article-title":"Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing","volume":"81","author":"Yeo","year":"2013","journal-title":"Lung Cancer"},{"key":"10.25259\/Cytojournal_18_2021\/ref-24","doi-asserted-by":"publisher","first-page":"e89946","DOI":"10.1371\/journal.pone.0089946","article-title":"Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"}],"container-title":["Cytojournal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cytojournal.com\/adequacy-of-pleural-fluid-cytology-for-comprehensive-molecular-analysis-of-lung-adenocarcinoma-experience-of-a-large-health-care-system\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cytojournal.com\/adequacy-of-pleural-fluid-cytology-for-comprehensive-molecular-analysis-of-lung-adenocarcinoma-experience-of-a-large-health-care-system\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:14:46Z","timestamp":1734527686000},"score":1,"resource":{"primary":{"URL":"https:\/\/cytojournal.com\/adequacy-of-pleural-fluid-cytology-for-comprehensive-molecular-analysis-of-lung-adenocarcinoma-experience-of-a-large-health-care-system\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":24,"alternative-id":["10.25259\/Cytojournal_18_2021"],"URL":"https:\/\/doi.org\/10.25259\/cytojournal_18_2021","relation":{},"ISSN":["1742-6413","0974-5963"],"issn-type":[{"value":"1742-6413","type":"electronic"},{"value":"0974-5963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"article-number":"7"}}